Nanjing's iPSC therapy reverses heart failure in 90% of patients in trial

In a landmark phase 2 clinical study, Nanjing Drum Tower Hospital (affiliated with Nanjing University) demonstrated that induced pluripotent stem cell (iPSC)-derived heart muscle cells can effectively treat severe heart failure. The long-term follow-up results, published in Nature Medicine on Wednesday, involved patients who received injections of lab-grown heart muscle cells alongside standard bypass surgery. At the 12-month mark, nine out of ten treated patients showed significantly improved cardiac function compared with the control group, which received only conventional treatment. The therapy capitalizes on iPSCs—adult cells reprogrammed to an embryonic-like state—which are then guided to become beating heart muscle cells. For a condition where dead muscle cannot regenerate naturally, this approach offers a way to grow new tissue and restore pumping ability.

The implications are substantial, particularly in regions with limited access to heart transplants. Severe heart failure leaves patients breathless after minimal activity, unable to sleep flat, and dependent on frequent hospitalizations. While transplant remains the only cure, donor hearts are exceedingly scarce. This cellular therapy could bridge that gap, potentially reducing long-term dependency on inotrope support and improving quality of life. The researchers noted that patients who received the iPSC-derived cells performed better on cardiac function tests, including ejection fraction and exercise capacity, with no serious safety signals observed over the year-long follow-up. Larger phase 3 trials will be needed to confirm efficacy and establish regulatory approval, but this 90% response rate marks a dramatic step forward for regenerative cardiovascular medicine. The study also opens avenues for using similar approaches in other muscle-loss conditions, positioning China’s biotech sector at the forefront of experimental cell therapy.